Literature DB >> 9054941

Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.

W C Nichols1, D L Koller, B Slovis, T Foroud, V H Terry, N D Arnold, D R Siemieniak, L Wheeler, J A Phillips, J H Newman, P M Conneally, D Ginsburg, J E Loyd.   

Abstract

Primary pulmonary hypertension (PPH), an often fatal disease, is characterized by elevated pulmonary artery pressures in the absence of a secondary cause. Endovascular occlusion in the smallest pulmonary arteries occurs by proliferation of cells and matrix, with thrombus and vasospasm. Diagnosis is often delayed because the initial symptoms of fatigue and dyspnea on exertion are nonspecific and definitive diagnosis requires invasive procedures. The average life expectancy after diagnosis is two to three years with death usually due to progressive right heart failure. The aetiology of the disease is unknown. Although most cases appear to be sporadic, approximately 6% of cases recorded in the NIH Primary Pulmonary Hypertension Registry are inherited in an autosomal dominant manner with reduced penetrance. Following a genome-wide search using a set of highly polymorphic short tandem repeat (STR) markers and 19 affected individuals from six families, initial evidence for linkage was obtained with two chromosome 2q markers. We subsequently genotyped patients and all available family members for 19 additional markers spanning approximately 40 centiMorgans (cM) on the long arm of chromosome 2. We obtained a maximum two-point lod score of 6.97 at theta = 0 with the marker D2S389; multipoint linkage analysis yielded a maximum lod score of 7.86 with the marker D2S311. Haplotype analysis established a minimum candidate interval of approximately 25 cM.

Entities:  

Mesh:

Year:  1997        PMID: 9054941     DOI: 10.1038/ng0397-277

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  48 in total

Review 1.  Primary pulmonary hypertension: the pressure rises for a gene.

Authors:  J R Thomson; R C Trembath
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

Review 2.  Primary pulmonary hypertension in childhood.

Authors:  S G Haworth
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 4.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 5.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

Review 6.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 7.  Pulmonary hypertension, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 8.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

9.  The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion.

Authors:  J E Loyd; B Slovis; J A Phillips; M G Butler; T M Foroud; P M Conneally; J H Newman
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

10.  Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases.

Authors:  K G Becker; R M Simon; J E Bailey-Wilson; B Freidlin; W E Biddison; H F McFarland; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.